Vincerx Pharma, Inc. Research and Development Expense (Excluding Acquired in Process Cost)
Vincerx Pharma, Inc. reported Research and Development Expense (Excluding Acquired in Process Cost) of $1.02 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2025-05-15
- Vincerx Pharma, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-03-31 was $1.02M, a 77.66% decline year-over-year.
- Vincerx Pharma, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2024-12-31 was $3.27M, a 11.98% decline year-over-year.
- Vincerx Pharma, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2024-09-30 was $3.91M, a 35.94% decline year-over-year.
- Vincerx Pharma, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2024-06-30 was $3.75M, a 54.49% decline year-over-year.
- Vincerx Pharma, Inc. research and development expense (excluding acquired in process cost) for fiscal 2024 was $15.49M, a 46.55% decline from fiscal 2023.
- Vincerx Pharma, Inc. research and development expense (excluding acquired in process cost) for fiscal 2023 was $28.97M, a 41.86% decline from fiscal 2022.
- Vincerx Pharma, Inc. research and development expense (excluding acquired in process cost) for fiscal 2022 was $49.84M, a 24.34% increase from fiscal 2021.
- Vincerx Pharma, Inc. research and development expense (excluding acquired in process cost) for fiscal 2021 was $40.08M, a 1794.19% increase from fiscal 2020.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 3 month as first filed | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month as first filed | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-03-31 | $1.02M 10-Q · filed 2025-05-15 | $4.29M derived: sum of 2 quarters · filed 2025-05-15 | $8.19M derived: sum of 3 quarters · filed 2025-05-15 | $11.95M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2024-12-31 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $7.18M derived: sum of 2 quarters · filed 2025-03-27 | $10.93M derived: sum of 3 quarters · filed 2025-03-27 | $15.49M 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $3.91M 10-Q · filed 2024-11-12 | $7.66M derived: sum of 2 quarters · filed 2024-11-12 | $12.22M 10-Q · filed 2024-11-12 | $15.93M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2024-06-30 | $3.75M 10-Q · filed 2024-08-08 | $8.31M 10-Q · filed 2024-08-08 | $12.02M derived: sum of 3 quarters · filed 2025-05-15 | $18.12M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2024-03-31 | $4.56M 10-Q · filed 2025-05-15 | $8.27M derived: sum of 2 quarters · filed 2025-05-15 | $14.37M derived: sum of 3 quarters · filed 2025-05-15 | $22.62M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $9.81M derived: sum of 2 quarters · filed 2025-03-27 | $18.06M derived: sum of 3 quarters · filed 2025-03-27 | $28.97M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $6.10M 10-Q · filed 2024-11-12 | $6.80M 10-Q · filed 2023-11-14 | $14.35M derived: sum of 2 quarters · filed 2024-11-12 | $25.26M 10-Q · filed 2024-11-12 | $34.32M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $8.25M 10-Q · filed 2024-08-08 | $7.87M 10-Q · filed 2023-08-07 | $19.16M 10-Q · filed 2024-08-08 | $18.46M 10-Q · filed 2023-08-07 | $28.22M derived: sum of 3 quarters · filed 2024-08-08 | $39.28M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $10.91M 10-Q · filed 2024-05-14 | $10.59M 10-Q · filed 2023-05-11 | $19.97M derived: sum of 2 quarters · filed 2024-05-14 | $31.04M derived: sum of 3 quarters · filed 2024-05-14 | $44.78M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $9.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $20.12M derived: sum of 2 quarters · filed 2024-03-29 | $33.87M derived: sum of 3 quarters · filed 2024-03-29 | $49.84M 10-K · filed 2024-03-29 | $52.15M 10-K · filed 2023-03-28 | ||
| 2022-09-30 | $11.07M 10-Q · filed 2023-11-14 | $24.81M derived: sum of 2 quarters · filed 2023-11-14 | $40.78M 10-Q · filed 2023-11-14 | $53.12M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $13.74M 10-Q · filed 2023-08-07 | $29.71M 10-Q · filed 2023-08-07 | $42.05M derived: sum of 3 quarters · filed 2023-08-07 | $54.26M derived: sum of 4 quarters · filed 2023-08-07 | |||
| 2022-03-31 | $15.97M 10-Q · filed 2023-05-11 | $28.31M derived: sum of 2 quarters · filed 2023-05-11 | $40.52M derived: sum of 3 quarters · filed 2023-05-11 | $51.22M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $12.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $24.55M derived: sum of 2 quarters · filed 2023-03-28 | $35.25M derived: sum of 3 quarters · filed 2023-03-28 | $40.08M 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $12.21M 10-Q · filed 2022-11-10 | $22.91M derived: sum of 2 quarters · filed 2022-11-10 | $27.74M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $10.70M 10-Q · filed 2022-08-11 | $15.53M 10-Q · filed 2022-08-11 | |||||
| 2021-03-31 | $4.83M 10-Q · filed 2022-05-12 | ||||||
| 2020-12-31 | $2.12M 10-K · filed 2022-03-29 |